MASSDEVICE ON CALL — Diagnostics and stents maker Volcano (NSDQ:VOLC) may be primed for acquisition, with a raft of analysts’ groups debating only the timing of a buy.
Volcano Corp.
Activist investor snaps up 5% of Volcano stock, demands changes
Volcano management discusses Q3 earnings results
Volcano plunges on lowered 2013 outlook
USPTO declines St. Jude Medical’s review request in patent in spat with Volcano
Medtronic hands Pioneer Plus catheters to Volcano in closed-doors deal
Volcano shares spike following rough Q2 report, upgrade from Wall Street
It’s been a roller-coaster ride for Volcano (NSDQ:VOLC) after posting Q2 earnings at the start of the week. The company posted red ink and missed analysts’ per-share estimates by 2 pennies, but Tuesday share prices jumped almost 8% based as 1 Wall Street analyst upgraded Volcano from "hold" to "buy."
Volcano gains on Street-beating Q2 earnings
Volcano extends deadline for $3M milestone payment for Crux Biomedical
The bulls may have run a little too far with St. Jude Medical
EuroPCR: Volcano, Boston Scientific team up for accurate stent placement study
Volcano Corporation (NSDQ:VOLC) and Boston Scientific (NYSE:BSX) announced a new, cosponsored Syntax study to test precision in stent placement.
The companies announced the upcoming study at the EuroPCR annual meeting in Paris, France.